Is #PDE5i protective in development of #SSc #ILD? Maybe 444 w ILD of >4000 #EUSTAR Pts over 1 to 2 yrs f/u #immunesuppressive use maybe or not 🤷‍♀️channeling bias Reduction in new #ILD in #scleroderma PDE5i ✅ Immunesuppression ? @RheumNow #EULAR2025 @eular_org #OP0334 https://t.co/6dtLfybkRV

#EULAR2025 Take Home message from Updated EULAR Recommendations @eular_org for #Lupus Nephritis: -Kidney Biopsy vital -Early use of Combination Therapies (HCQ + GC + Immunosuppressant + CNI/Belimumab/Obinutuzumab) -Severe: High dose Cyclo + GC @RheumNow https://t.co/jHFqdT1TLf

🔍MRI lesions in early axSpA vs non axSpA with chronic back pain: -Data from SPACE cohort -n 318 (214 axSpA vs 108 non-axSpA). -Baseline imaging (CR and MRI) and at 2y f/u -Minimal progression on CR in both early axSpA and non-axSpA CBP. -On MRI, significant increase in the https://t.co/m5YOAiFUz1

E3N cohort 78000+ women >30yrs follow up 698 incident RA cases) In non smokers, RA asso w/ -tall at birth HR=1.55 In smokers, RA risk associated w/ -prematurity HR=1.63 -in utero exposure to tobacco HR=1.83 (ns) #EULAR2025 @RheumNow POS0226 https://t.co/xC3k3kiKsZ

Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors The concept of D2M axSpA is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. https://t.co/KmfJvAtwp0

Secukinumab promise in PMR is real GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out. Most PMR patients with current therapy approaches incur multiple grams of cumulative prednisolone exposure, even though they’re often exactly the kind of https://t.co/GuD0l7zSfj

Among 200 #axSpA pts from Rheumazentrum Ruhrgebiet 🔴Performance tests (SPPB) were associated with 🔴Global functioning and health (ASAS-HI and other PROs) What does this mean? Improving physical performance could enhance PROs & QOL #EULAR2025 POS# @RheumNow @XBaraliakos https://t.co/P3Q5NDvtoj

#D2M_axSpA_saga 🇬🇷 Prevalence of D2M axSpA in 395 patients: 10.1% Associated factors: 🔹️High disease activity at diagnosis 🔹️Comorbidities (high BMI, smoking, depression) 🔹️Unemployment Kougkas et al. POS#0121 #EULAR2025 @rheumnow https://t.co/vcPcTATTx5

What's the difference between PIPsA & NIPsA? (Persistent Inflammatory confirmed by IMAGING vs. Non inflammatory PsA) 🔹️Cross-sectional study 🔹️517 pts under b/tsDMARDs 🔹️10.3% D2T 🔹️57% PIPsA / 43% NIPsA 👇 Distinct phenotypes 👇 OP0176 #EULAR2025 @rheumnow https://t.co/YGHpbeE6ws